Inhibition of the B cell associated tyrosine kinase SYK as a potential therapeutic target in aggressive lymphomas.

被引：0
|
作者：
Bertoni, F
Ridaidi, A
Sasso, A
Uccella, S
Martin, V
Napoli, S
Pruneri, G
Zucca, E
Capella, C
Catapano, CV
Tibiletti, MG
Cavalli, F
机构：
[1] Oncol Inst Sos Switzerland, Expt Oncol Lab, Bellinzona, Switzerland
[2] Oncol Inst Sos Switzerland, Lymphoma Unit, Bellinzona, Switzerland
[3] Univ Insubria, Osped Circolo, Anat Pathol Unit, Varese, Italy
[4] European Inst Oncol, Div Pathol & Lab Med, Milan, Italy
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1469
引用
收藏
页码：424A / 424A
页数：1
相关论文
共 50 条
  • [41] Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway
    Yu, Yu
    Rahmanto, Yohan Suryo
    Lee, Meng-Horng
    Wu, Pei-Hsun
    Phillip, Jude M.
    Huang, Chuan-Hsiang
    Vitolo, Michele I.
    Gaillard, Stephanie
    Martin, Stuart S.
    Wirtz, Denis
    Shih, Ie-Ming
    Wang, Tian-Li
    ONCOGENE, 2018, 37 (28) : 3778 - 3789
  • [42] Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer
    Kokabee, Leila
    Wang, Xianhui
    Sevinsky, Christopher J.
    Wang, Wei Lin Winnie
    Cheu, Lindsay
    Chittur, Sridar V.
    Karimipoor, Morteza
    Tenniswood, Martin
    Conklin, Douglas S.
    CANCER BIOLOGY & THERAPY, 2015, 16 (11) : 1604 - 1615
  • [43] The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma
    Tong, Xiangmin
    Zhang, Xuewu
    Fan, Jian
    Tong, Yin
    Li, Shuangshuang
    Jin, Jie
    Yao, Hangping
    CANCER BIOLOGY & THERAPY, 2013, 14 (04) : 370 - 377
  • [44] p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas.
    Fest, T
    Hernandez, L
    TeruyaFeldstein, J
    Cazorla, M
    Bosch, F
    Peinado, MA
    Piris, MA
    Montserrat, E
    Cardesa, A
    Jaffe, ES
    Raffeld, M
    Campo, E
    BLOOD, 1995, 86 (10) : 2112 - 2112
  • [45] Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia
    Perova, Tatiana
    Grandal, Ildiko
    Nutter, Lauryl M. J.
    Papp, Eniko
    Matei, Irina R.
    Beyene, Joseph
    Kowalski, Paul E.
    Hitzler, Johann K.
    Minden, Mark D.
    Guidos, Cynthia J.
    Danska, Jayne S.
    SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (236)
  • [46] Molecular characterization of a novel gene, bal, which regulates the proliferation of aggressive B-cell lymphomas.
    Yakushijin, Y
    Aguiar, R
    Steckel, J
    Kharbanda, S
    Freeman, G
    Shipp, MA
    BLOOD, 1997, 90 (10) : 782 - 782
  • [47] Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms
    Zhang, Jing-Ping
    Gao, Qi
    Chan, Alexander
    Xiao, Wenbin
    El Daker, Sary
    Roshal, Mikhail
    Dogan, Ahmet
    BLOOD, 2019, 134
  • [48] Activation of the endoplasmic reticulum (ER) unfolded protein response (UPR) in aggressive B-cell lymphomas.
    Balague, Olga
    Colomo, Luis
    Lopez-Guillermo, Armando
    Campo, Elias
    Martinez, Antonio
    BLOOD, 2006, 108 (11) : 577A - 577A
  • [49] Rituximab plus CHOP for the treatment of Sjogrens syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis, M
    Giannouli, S
    Anagnostou, D
    Tzioufas, AG
    Tzioufas, AG
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S575 - S575
  • [50] Protein tyrosine phosphatase 1B inhibition as a potential therapeutic target for chronic wounds in diabetes
    Figueiredo, Ana
    Leal, Ermelindo C.
    Carvalho, Eugenia
    PHARMACOLOGICAL RESEARCH, 2020, 159
12345